eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2017
vol. 21
 
Share:
Share:
more
 
 
abstract:
Review paper

Radioembolization treatment for liver metastases

Joanna Kiszka, Bożenna Karczmarek-Borowska

Contemp Oncol (Pozn) 2017; 21 (4): 274-278
Online publish date: 2017/12/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The liver is an organ that, due to vascularisation and functions, is prone to metastases. Most liver metastases are observed in cases of gastrointestinal cancers in: stomach, colon, gallbladder, and bile ducts. Metastatic lesions are also observed in lung, breast, thyroid, kidney, and pancreatic cancer. One of the best known and most effective ways of liver lesion treatment is Metastasectomy. Unfortunately, lesions are frequently inoperable. Apart from chemotherapy, it is possible to apply local treatment such as TACE (trans-arterial chemoembolisation), RFA (Radio Frequency Ablation), and SBRT (Stereotactic Body Radiation Therapy). One of the newest methods of inoperable lesion treatment is radioembolisation (SIRT). Intravascular administration of microspheres containing radioisotope 90Y allows delivery of a higher dose of radiation directly to the tumour than traditional radiation with an external beam, while maintaining a small dose to healthy liver methods. Conducted clinical studies confirm the efficacy and safety of SIRT. It is an interesting alternative to other ways of treatment.
keywords:

liver metastases, hepatocellular carcinoma, radioembolisation

references:
Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. BMJ 2000; 321: 805-8.
Page AJ, Cosgrove DC, Herman JM, Pawlik TM. Advances in understanding of colorectal liver metastasis and implications for the clinic. Expert Rev Gastroenterol Hepatol 2015; 9: 245-59.
ltekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
Scorsetti M, Comito T, Tozzi A, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 2015; 141: 543-53.
Comito T, Cozzi L, Clerici E, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 2014; 14: 619
Janoray G, Mornex F. Follow-up after stereotactic body radiation therapy for liver tumours: A review of the literature and recommendations. Cancer Radiother 2015; 19: 573-81.
Vavra P, Novakova J, Ostruszka P, et al. Colorectal cancer liver metastases: laparoscopic and open radiofrequency-assisted surgery. Videosurgery Miniinv 2015; 10: 205-12.
Sorensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007; 48: 253-8.
Kariyama K, Wakuta A, Nishimura M, et al. Percutaneous Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma. Oncology 2015; 89 Suppl 2: 19-26.
Niu R, Yan TD, Zhy JC, et al. Recurrence and survival outcomes after hepatic resection with or without cryotherapy of liver metastases from colorectal carcinoma. Ann Surg Oncol 2007; 14: 2078-2087.
Lammer J, Malagari K, Vogl T. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: result of PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 2011; 7: 463-75.
Bester L, Meteling B, Boshell D, et al. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature. J Med Imaging Radiat Oncol 2014; 58: 341-52.
Huang W, Yang S, You L, et al. Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemp Oncol (Pozn) 2016; 20: 468-74.
Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. Therapy response of liver tumors after selective internal radiation therapy. Radiologe 2008; 48: 839-49.
Damm R, Seidensticker R, Ricke J, Seidensticker M. Interventional radiological procedures in the therapy for colorectal liver metastases. Zentralbl Chir 2013; 138: 76-83.
Bester L, Hobbins PG, Wang SC, Salem R. Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer J Med Imaging Radiat Oncol 2011; 55: 111-8.
Raoul JL, Edeline J, Pracht M, Boucher E, Rolland Y, Garin E. Radioembolisation for hepatocellular carcinoma. Cancer Radiother 2011; 15: 64-8.
Llovet JM, Joshi J., Brux J. Barcelona-Clinic Liver Cancer Group.: The Barcelona approach: diagnosis, staging and treatment of hepatocellular carcinoma. Liver Transpl 2004;10 (2 Suppl 1): S115-20.
Strigari L, Sciuto R, Rea S, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010; 51: 1377-85.
Lam MG, Louie JD, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol 2013; 36: 1320-8.
Townsend A, Price TJ, Patterson K, Pittman K. Fluorouracil-induced hepatic artery spasm preventing yttrium-90 microsphere administration. Clin Nucl Med 2008; 33: 528-30.
van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: Randomised Phase III Trial Comparing First-Line m Folfox6 (plus or minus Bevacizumab) versus mFOLFOX6 (plus or minus Bevacizumab) plus Selective Internal Radiation Therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34: 1723-31.
Dutton SJ, Kenealy N, Love SB, et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer 2014; 14: 497.
van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009; 27: 4089-95.
Bhangoo MS, Karnani DR, Hein PN, et al. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015; 6: 469-78.
Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials 2014; 15: 474.
Thelen A, Jonas S, Benckert C, et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis 2007; 22: 1269-76.
Smitzu Y, Yasui K, Sano T, et al. Treatment strategy for synchronous metastases of colorectal cancer: is hepatic resection after an observation interval appropriate? Langenbeck’s Arch Surg 2007; 392: 535-8.
Yan TD, Chu F, Black D, et al. Synchronous resection of colorectal primary cancer and liver metastases. World J Surg 2007; 31: 1496-501.
Thelen A, Jonas S, Benckert C. Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol 2007; 33: 324-8.
Nisho H, Hamady ZZR, Malik HZ. Outcome following repeat liver resection for colorectal liver metastases. Eur J Surg Oncol 2007; 33: 729-34.
Bydder S, Spry NNA, Christie DR, Roos D, Burmeister BH, Krawitz H. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australas Radiol 2003; 47: 284-8.
Hoyer M, Swaminath A, Bydder S, Lock M, Mendez RA, Kavanagh B. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 2012; 82: 1047-57.
Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med 2015; 66: 83-95.
Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20: 10316-30.
Juez I, Rubio C, Figueras J. Multidisciplinary approach of colorectal liver metastases. Clin Transl Oncol 2011; 13: 721-7.
Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clin Colorectal Cancer 2016; 15: 1-6.
Wang G, Kelley RK. Gappnet. KRAS mutational analysis for colorectal cancer: Application pharmacogenomic. PLoS Curr 2010; 2; DOI: 10.1371/currents.RRN1175.
Keating GM. Spotlight on panitumumab in metastatic colorectal cancer. BioDrugs 2010; 24: 275-8.
Lakomy R, Rogowski W, Piko B, Mihaylova Zh, Pritzova E, Kvocekova L. Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study. Cancer Manag Res 2015; 7: 311-8.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe